Home / Market News / $SLGL
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Sol-Gel Technologies Reports Third Quarter 2026 Financial Results and Corporate Updates

Nov 13, 2026, 7:04 AM UTC · Primary ticker $SLGL

Sol-Gel Technologies reported a slightly reduced net loss for Q3 2026 and provided an update on its SGT-610 clinical trial, with top-line results expected in late November 2026. The company also confirmed sufficient cash to fund operations into Q1 2028 and its intent to retain U.S. commercial rights for SGT-610, indicating a potential future revenue stream.

Sol-Gel Technologies (SLGL) reported its Q3 2026 financial results, showing a net loss of $5.6 million, a slight improvement from the prior year. The key development, however, is the completion of the last patient last visit for its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, with top-line results anticipated in late November 2026. This clinical milestone is significant as positive results could lead to regulatory submission and potential commercialization, which the company intends to handle itself in the U.S. This news provides a near-term catalyst for SLGL, as the market will closely watch for the trial results. The company's cash runway into Q1 2028 provides financial stability for the immediate future, but the long-term outlook hinges heavily on the success of SGT-610.

$SLGL neutral Primary subject of financial and clinical updates
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.